Muscle loss on GLP-1: what the LEAN-PREP trial reveals about prevention

The muscle loss problem on GLP-1 medications is real. Clinical trial data shows 25-40% of total weight lost comes from lean mass, not fat. That percentage rises when protein intake is low and resistance training is absent. But the loss is not inevitable - it is a function of the caloric deficit without adequate structural support. A new randomised controlled trial called LEAN-PREP, launched in Kuwait in 2025 and now enrolling participants, is testing whether a specific combination of resistance exercise and high-dose protein can preserve muscle while losing fat on semaglutide and tirzepatide. The trial design reveals what evidence-based muscle preservation looks like in practice.

TL;DR

LEAN-PREP is a 232-person 6-month RCT testing whether resistance exercise plus 1.6 g/kg/day protein prevents muscle loss on semaglutide/tirzepatide. Primary outcome is quadriceps muscle cross-sectional area on MRI. The trial is testing the specific interventions known to work - the threshold protein intake and exercise frequency that current evidence supports. Results are expected 2026.

Why LEAN-PREP was designed the way it was

The researchers chose their interventions based on what the existing evidence already established. Protein intake at 1.2-1.6 g/kg/day is the threshold recommended by a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Below 1.2, muscle loss accelerates. Above 1.6, additional benefit diminishes.

Resistance training at three sessions per week is the frequency at which studies consistently show muscle preservation during weight loss. It does not require a gym - bodyweight exercises, bands, or light dumbbells are sufficient. The key is progressive load: the work must be challenging enough to signal muscle fibres that they are needed.

The trial is not testing whether these interventions might work - the evidence base already shows they do. LEAN-PREP is testing how well they work in the real-world context of GLP-1 therapy, and whether combining them produces additive protection compared to each alone.

The LEAN-PREP trial design

The trial is based at the Dasman Diabetes Institute in Kuwait, a country with one of the world's highest obesity prevalences and corresponding high rates of GLP-1 medication use. The target enrollment is 232 adults with BMI 27-45 kg/m², randomised to one of four parallel groups:

• Control (usual habits maintained)
• Resistance exercise alone
• Protein supplementation alone (2g protein drinks daily, adjusted after dietary assessment)
• Combined resistance exercise + protein

All participants receive either semaglutide or tirzepatide for diabetes management, the standard background therapy. The study duration is 6 months, with the primary outcome being quadriceps muscle cross-sectional area measured on MRI at the midthigh level.

The exercise protocol

The resistance protocol is deliberately practical. Three sessions per week, home-based (no gym required), targeting seven major muscle groups: squats, push-ups, lunges, rows, shoulder raises, calf raises, and planks. Progressive intensity is built in: single sets in week 1, progressing to three sets by week 5. Exertion is monitored using the OMNI-RES scale (a perceived exertion rating that ensures the work is challenging enough to produce adaptation).

This is not competitive bodybuilding. It is the minimum effective dose of resistance training to preserve muscle during weight loss - a frequency and intensity that most adults can sustain for 6 months without excessive disruption to their schedule.

The protein protocol

Target protein is 1.6 g/kg/day - at the higher end of the evidence-supported range. For a 100 kg (220 lb) person, this translates to 160g protein daily. The trial provides two protein drinks of 25g each daily, reducing the burden of achieving this through food alone. After 2 weeks, individual dietary assessment adjusts the supplementation based on how much protein the participant is consuming through regular food.

This is important because the trial is not just testing passive supplementation - it is testing whether adding structured protein support helps people hit the threshold that the literature already supports, acknowledging that many GLP-1 users fail to reach 1.2-1.6 g/kg purely through food due to appetite suppression and the practicality of eating enough while feeling full.

What LEAN-PREP will measure beyond muscle

The primary outcome is muscle mass (quadriceps CSA), but the trial is measuring multiple important secondary outcomes that paint a fuller picture of the intervention's effects:

• Body composition (DEXA scan) - total fat loss, lean mass preservation, and visceral fat reduction
• Liver health (MRI elastography) - liver fat and stiffness, important given the metabolic context
• Muscle strength and function (grip strength, gait speed, chair rise time, balance) - real-world functional capacity, not just tissue quantity
• Glycemic control and metabolic markers - whether adding exercise and protein affects the metabolic benefits of GLP-1 drugs
• Physical activity, sleep quality, quality of life (questionnaires) - the lived experience of treatment

The breadth of outcomes reflects what matters in real life: you want to lose fat, preserve muscle mass, maintain strength and function, keep blood sugar controlled, and feel good doing it. LEAN-PREP tests all of these simultaneously.

Why this trial matters right now

GLP-1 medications are driving weight loss at scale. Millions of people globally are losing substantial amounts of weight on these drugs. The quality of that weight loss - the ratio of fat to lean mass - depends on the choices they make about protein and exercise. LEAN-PREP is the first rigorous test of whether the interventions that have worked in non-GLP-1 weight loss contexts work equally well when the appetite-suppressing power of these drugs is in play.

The findings will inform clinical guidelines and patient education. If the combined intervention (exercise + protein) proves superior to either alone, that becomes the standard recommendation. If single interventions suffice, resources can be directed more efficiently. Either way, the trial will provide evidence-based numbers for practitioners to cite when talking to patients about what actually preserves lean mass.

Applying LEAN-PREP principles right now

If you are on a GLP-1 medication and want to protect your muscle mass while losing weight, you do not need to wait for LEAN-PREP results - the evidence base already supports these interventions:

Protein target: 1.2-1.6 g/kg/day

For a 100 kg person, this is 120-160g daily. Distribute it across meals and snacks. If appetite suppression makes reaching this through food difficult, protein supplements (powder, ready-to-drink) are an efficient way to close the gap.

Resistance exercise: 3x/week

Bodyweight is sufficient. Aim for major muscle groups: legs, chest, back, core. Progressive load matters - each session should feel challenging. Home-based counts; you do not need a gym.

Micronutrient support

Magnesium, zinc, and vitamin D all support muscle protein synthesis. These are among the nutrients most commonly depleted when food intake drops substantially on GLP-1 therapy. Targeted supplementation ensures your muscle has the micronutrient environment it needs to respond to the training stimulus.

Nutrient foundations for muscle preservation

GLP-1 Shield is formulated around the specific nutrient gaps that GLP-1 medications create, including the micronutrients that support muscle protein synthesis, strength, and recovery. While you are working on the exercise and protein intake side, ensuring adequate micronutrient status is the complementary intervention that completes the picture.

Frequently asked questions

How much muscle is lost on Ozempic or Wegovy?

Clinical trial data shows 25-40% of total weight lost comes from lean mass, not fat. This percentage can be higher if protein intake is low and resistance training is absent. It can be substantially reduced with adequate protein (1.2-1.6 g/kg/day) and resistance exercise three times per week.

What is the LEAN-PREP trial testing?

LEAN-PREP is a 232-person, 6-month randomised trial testing whether resistance exercise plus 1.6 g/kg/day protein prevents muscle loss on semaglutide or tirzepatide. The primary outcome is quadriceps muscle size measured on MRI. Results are expected in 2026.

Can I preserve muscle while on GLP-1 medications right now?

Yes. The evidence base already supports the interventions LEAN-PREP is formally testing: at least 1.2 g/kg/day protein (higher is better up to 1.6), and resistance exercise three times per week targeting major muscle groups. Progressive load and consistency matter more than intensity or equipment.

Do I need a gym to do resistance training on GLP-1?

No. Bodyweight exercises - squats, push-ups, lunges, rows, planks - are sufficient. Progressive load can be achieved through increasing reps, sets, or range of motion. Bands or light dumbbells can supplement bodyweight exercises, but they are not required.